MedTrace Logo

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

NCT03855696 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2021-10-26

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of MG1113 in the single ascending dose study (IV injection or SC injection) in healthy subjects and hemophiia patients.

Conditions

Interventions

BIOLOGICAL

MG1113

MG1113

OTHER

Placebo of MG1113

Placebo of MG1113

Sponsors & Collaborators

  • Dream CIS, Inc.

    collaborator INDUSTRY

  • Green Cross Corporation

    lead INDUSTRY

Principal Investigators

  • Ji-Young Park, MD · Korea University Anam Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-21
Primary Completion
2021-06-30
Completion
2021-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03855696 on ClinicalTrials.gov